Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted a market filing for its chemical drug SBK010 for review.
SBK010, which is licensed from Chengdu Shibekang Biomedical Technology Co., Ltd, another Chinese firm, is intended for the treatment of patients with mild to moderate acute ischemic stroke.- Flcube.com
